-
Updated Immunization Guidelines from the CDC; Do antivirals have a role in the treatment of Bell's palsy? Topiramate is a promising treatment for alcohol dependence; and FDA Actions.
-
Though a U.S. Supreme Court hearing for the case of Riegel v. Medtronic took only slightly more than an hour in early December, the effects of the High Court's decision will have major, long-lasting impact on the medical device industry —and, potentially also, for litigators who handle, or won't, medical device product liability cases.
-
An FDA panel recently recommended approval of Kynapid but rejected giving a recommendation to Pulzium to treat atrial fibrillation (AF), a condition in which panel of federal advisers this week told the FDA that it should approve Kynapid and Pulzium to treat atrial fibrillation (AF).
-
Cardiome Pharma (Vancouver) said interim results from its Phase IIb trial with oral vernakalant to prevent recurrence of atrial fibrillation (AF), originally due in 4Q07, will not be disclosed until March of 2008, with final data in the middle of the next year.
-
The race is on — or at least the participants have entered the starting gate.
-
This year's annual meeting of the American Heart Association (Dallas) featured a rather odd report, that report describing the successful slowing of a female patient's atrial fibrillation (AF) with a rather unusual technique.
-
LONDON — ReNeuron (Guildford, UK) in early December submitted the further data requested in the investigational new drug file for its stem cell treatment for stroke, keeping it on track to be the first to carry out an FDA-approved trial of neural stem cells in a major neurological disorder. The file, originally submitted a year ago, was put on hold in January.
-
Angiotech Pharmaceuticals (Vancouver, British Columbia) and The Atlanta Cardiology Group (ACG; Atlanta, Georgia) reported signing an agreement formalizing an affiliation with Piedmont Healthcare (Atlanta,) as part of the Piedmont Heart Institute, effective Nov. 15 of this year.
-
Physio-Control (Redmond, Washington), which makes Lifepak brand defibrillators, confirmed earlier this week that it is on track to resume full shipments by April 30 and that it is making progress toward improving previously reported problems.
-
3M (St. Paul, Minnesota) and Zargis Medical (Princeton, New Jersey) reported an exclusive multi-year marketing agreement.
